NCT03543306View on ClinicalTrials.gov

Dabrafenib and Trametinib in Patients With Non-small Cell Lung Cancer Harboring V600E BRAF Mutation

PHASE2UnknownINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

June 30, 2018

Primary Completion Date

June 30, 2020

Study Completion Date

June 30, 2022

Conditions
CancerLung Cancer MetastaticBRAF V600E
Interventions
DRUG

daborafenib plus trametinib

Dabrafenib 150 mg twice daily and trametinib 2 mg once daily

Trial Locations (1)

138-736

RECRUITING

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Asan Medical Center

OTHER